- Home
- NUWE vs JAGX Comparison
NUWE vs JAGX Comparison
Compare NUWE & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- JAGX
- Stock Information
- Founded
- NUWE 1999
- JAGX 2013
- Country
- NUWE United States
- JAGX United States
- Employees
- NUWE N/A
- JAGX N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- JAGX Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- JAGX Health Care
- Exchange
- NUWE Nasdaq
- JAGX Nasdaq
- Market Cap
- NUWE 3.9M
- JAGX 3.4M
- IPO Year
- NUWE N/A
- JAGX N/A
- Fundamental
- Price
- NUWE $5.22
- JAGX $1.80
- Analyst Decision
- NUWE
- JAGX Strong Buy
- Analyst Count
- NUWE 0
- JAGX 1
- Target Price
- NUWE N/A
- JAGX $60.00
- AVG Volume (30 Days)
- NUWE 255.1K
- JAGX 96.8K
- Earning Date
- NUWE 08-14-2025
- JAGX 08-14-2025
- Dividend Yield
- NUWE N/A
- JAGX N/A
- EPS Growth
- NUWE N/A
- JAGX N/A
- EPS
- NUWE N/A
- JAGX N/A
- Revenue
- NUWE $8,318,000.00
- JAGX $11,810,000.00
- Revenue This Year
- NUWE $6.53
- JAGX $22.41
- Revenue Next Year
- NUWE $51.63
- JAGX $30.00
- P/E Ratio
- NUWE N/A
- JAGX N/A
- Revenue Growth
- NUWE N/A
- JAGX 15.96
- 52 Week Low
- NUWE $4.82
- JAGX $1.78
- 52 Week High
- NUWE $175.98
- JAGX $35.25
- Technical
- Relative Strength Index (RSI)
- NUWE 33.36
- JAGX 33.66
- Support Level
- NUWE $4.82
- JAGX $2.02
- Resistance Level
- NUWE $6.72
- JAGX $2.65
- Average True Range (ATR)
- NUWE 0.44
- JAGX 0.18
- MACD
- NUWE 0.21
- JAGX -0.00
- Stochastic Oscillator
- NUWE 21.05
- JAGX 2.30
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About JAGX Jaguar Health Inc.
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.